Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6616 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-05-05 (pharmabiz.net)
STATE: PUJA BETWEEN SPINRAZA AND LIGONUX -
Nusinersen, the treatment for spinal muscular atrophy, stars in a new public purchase. And for the first time, there are two different options for their acquisition. See tender so far, the only therapeutic option carried the signature of the American Biogen, which was presented with its eminraza treatment. However, in October […]
Read more
2025-04-10 (thepharma.media)
Organon acquires the rights to Actemra biosymyr in the United States
Bio-Thera Solutions, the developer of bioanalog, will continue to own the rights to produce a product.
Read more
2025-04-02 (pharmaceutical-technology.com)
Organon acquires Actemra biosimilar's US rights from Biogen
Organon has announced the acquisition from Biogen of US regulatory and commercial rights for intravenous infusion of Tofidence.
Read more
2025-03-04 (bizjournals.com)
Biogen continues dealmaking buzz with Stoke Therapeutics
Biogen Inc. is making good on its promise to focus on "external opportunities," this time with a new deal involving a Bedford-based biotech.
Read more